Details
Stereochemistry | RACEMIC |
Molecular Formula | C13H16N4O6.ClH |
Molecular Weight | 360.75 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.[O-][N+](=O)C1=CC=C(O1)\C=N\N2CC(CN3CCOCC3)OC2=O
InChI
InChIKey=PPSVFZXMDMUIGB-FJUODKGNSA-N
InChI=1S/C13H16N4O6.ClH/c18-13-16(14-7-10-1-2-12(22-10)17(19)20)9-11(23-13)8-15-3-5-21-6-4-15;/h1-2,7,11H,3-6,8-9H2;1H/b14-7+;
Molecular Formula | C13H16N4O6 |
Molecular Weight | 324.2893 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 1 |
Optical Activity | ( + / - ) |
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Furaltadone is a veterinary product, which is marketed for the treatment and control of salmonella infection of poultry. In 1960th was investigated the antibacterial properties of this drug against human Rhodesian sleeping sickness. In three cases treated, two were apparently curated and the third relapsed. No toxic effects attributable to the product had been observed. However, the further investigation of the furaltadone in human was not provided.
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/13681531
oral: 250 mg every 6 hour
intravenous: 500 mg
Route of Administration:
Other
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:39:31 GMT 2023
by
admin
on
Fri Dec 15 16:39:31 GMT 2023
|
Record UNII |
37Q02H7JT2
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
9576185
Created by
admin on Fri Dec 15 16:39:31 GMT 2023 , Edited by admin on Fri Dec 15 16:39:31 GMT 2023
|
PRIMARY | |||
|
37Q02H7JT2
Created by
admin on Fri Dec 15 16:39:31 GMT 2023 , Edited by admin on Fri Dec 15 16:39:31 GMT 2023
|
PRIMARY | |||
|
223-169-4
Created by
admin on Fri Dec 15 16:39:31 GMT 2023 , Edited by admin on Fri Dec 15 16:39:31 GMT 2023
|
PRIMARY | |||
|
SUB02285MIG
Created by
admin on Fri Dec 15 16:39:31 GMT 2023 , Edited by admin on Fri Dec 15 16:39:31 GMT 2023
|
PRIMARY | |||
|
DTXSID5045380
Created by
admin on Fri Dec 15 16:39:31 GMT 2023 , Edited by admin on Fri Dec 15 16:39:31 GMT 2023
|
PRIMARY | |||
|
100000087020
Created by
admin on Fri Dec 15 16:39:31 GMT 2023 , Edited by admin on Fri Dec 15 16:39:31 GMT 2023
|
PRIMARY | |||
|
3759-92-0
Created by
admin on Fri Dec 15 16:39:31 GMT 2023 , Edited by admin on Fri Dec 15 16:39:31 GMT 2023
|
PRIMARY | |||
|
53270
Created by
admin on Fri Dec 15 16:39:31 GMT 2023 , Edited by admin on Fri Dec 15 16:39:31 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE | |||
|
ENANTIOMER -> RACEMATE | |||
|
ENANTIOMER -> RACEMATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |